# Raltegravir One Thousand Two Hundred vs Darunavir-cb in Immnunosupressed Patients: ROTDIP Study

> **NCT03842488** · PHASE4 · UNKNOWN · sponsor: **Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud** · enrollment: 75 (estimated)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Experimental: RAL QD
- **DRUG:** Active comparator: DRV/cb

## Key facts

- **NCT ID:** NCT03842488
- **Lead sponsor:** Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-04
- **Primary completion:** 2021-03
- **Final completion:** 2021-03
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2019-02-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03842488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03842488, "Raltegravir One Thousand Two Hundred vs Darunavir-cb in Immnunosupressed Patients: ROTDIP Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03842488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*